“Altered endocannabinoid (eCB) signaling is suggested as an important contributor to the pathophysiology of depression.
In summary, our data suggest a decreased eCB signalling in the FSL rats, which could contribute to the depressive-like behaviour.
Interestingly, the altered eCB system activity appear to be hemisphere-specific in the limbic regions.
Our study support the existing literature and showed altered eCB system activity in this particular animal model of depression.”
https://www.ncbi.nlm.nih.gov/pubmed/30716357
https://www.sciencedirect.com/science/article/abs/pii/S0197018618305151?via%3Dihub
“Major depressive disorder is a devastating psychiatric disease that afflicts up to 17% of the world’s population. Postmortem brain analyses and imaging studies of patients with depression have implicated basal lateral amygdala (BLA) dysfunction in the pathophysiology of depression. However, the circuit and molecular mechanisms through which BLA neurons modulate depressive behavior are largely uncharacterized. Here, in mice, we identified that BLA cholecystokinin (CCK) glutamatergic neurons mediated negative reinforcement via D2 medium spiny neurons (MSNs) in the nucleus accumbens (NAc) and that chronic social defeat selectively potentiated excitatory transmission of the CCKBLA-D2NAc circuit in susceptible mice via reduction of presynaptic cannabinoid type-1 receptor (CB1R). Knockdown of CB1R in the CCKBLA-D2NAc circuit elevated synaptic activity and promoted stress susceptibility. Notably, selective inhibition of the CCKBLA-D2NAc circuit or administration of synthetic cannabinoids in the NAc was sufficient to produce antidepressant-like effects. Overall, our studies reveal the circuit and molecular mechanisms of depression.”
“The present review will provide an overview of the neurobiology, epidemiology, clinical impact, and treatment of cannabis use disorder (CUD) in mood disorders.
“Cannabis sativa is one of the most popular recreational and medicinal plants. Benefits from use of 
